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Background: Achilles tendinopathy (AT) occurs in half of the elite runners. AT is 
a difficult-to-treat tendon disease, which may progress from new onset to a chronic 
state. It is unknown how many runners with new-onset AT develop persisting 
symptoms and which prognostic factors are associated with this course.
Objective: To describe how many runners develop persisting symptoms 1 year after 
onset of reactive AT.
Study Design: Prospective cohort study.
Methods: Runners registering for a Dutch running event (5-42.2 km) were eligible 
for inclusion. Runners reporting new-onset AT between registration for the running 
event and 1 month after received a 1-year follow-up questionnaire. The 1-year fol-
low-up questionnaire inquired about persisting symptoms (yes/no), running activity, 
and metabolic disorders. We calculated the percentage of runners with persisting 
symptoms and performed a multivariable logistic regression analysis to study the as-
sociation between potential prognostic factors and persisting symptoms.
Results: Of 1929 participants, 100 runners (5%) reported new-onset AT. A total of 
62 runners (62%) filled in the 1-year follow-up questionnaire. Persisting symptoms 
were reported by 20 runners (32%). A higher running distance per week before new-
onset AT was associated with a lower risk of developing persisting symptoms (odds 
ratio (OR): 0.9, 95% confidence interval (CI): [0.9;1.0]). There was a positive trend 
toward an association between metabolic disorders and persisting symptoms (OR: 
5.7, 95% CI: [0.9;36.2]).
Conclusion: One third of runners develop persisting symptoms 1 year after new-
onset AT. Interestingly, a higher running distance per week before new-onset AT 
potentially lowers the risk of developing persisting symptoms.
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1 |  INTRODUCTION
Running grows in popularity due to its health benefits 
and low costs, and the incidence of running-related inju-
ries is growing simultaneously.1 While acute sports in-
juries already rank third place in total healthcare costs,2 
the subgroup of athletes with chronic injuries account for 
even higher costs due to more medical visits and absence 
of work.3,4 One of the most common running injuries is 
Achilles tendinopathy (AT), with approximately half of the 
elite runners developing AT during their running career.5 
It is therefore important to accurately identify the number 
of runners that develop persisting symptoms and addition-
ally to identify prognostic factors for developing persisting 
symptoms.
The phases of AT are currently considered to be a spec-
trum ranging from new-onset tendinopathy to degenerative 
chronic tendinopathy.6 In new-onset AT, collagen integrity is 
considered to be normal, with the presence of increased cell 
proliferation.6 Chronic AT may develop when symptoms per-
sist or recur and is characterized by a loss of well-organized 
tendon tissue structure.6 We know that high activity levels 
and general health are important factors for the development 
of a chronic tendon disease.6 In case of general health, met-
abolic disorders are frequently associated with AT and AT is 
more prevalent in runners with a worse metabolic profile.7-9 
It is, however, unknown which percentage of runners with 
new-onset AT develop persisting symptoms and which prog-
nostic factors are associated with an increased risk of devel-
oping persisting symptoms.
The primary aim of this study was to describe the per-
centage of runners that develop persisting AT symptoms 
1 year after new-onset AT. Our secondary aims were to de-
scribe symptom severity in runners 1  year after develop-
ment of new-onset AT, the course of symptoms, healthcare 
consumption, and running activity, and to identify prognos-
tic factors that are associated with developing persisting 
symptoms.
2 |  METHODS
2.1 | Design
This prospective cohort study is a 1-year follow-up of run-
ners who were included in the INSPIRE trial (INtervention 
Study on Prevention of Injuries in Runners at Erasmus MC) 
and reported new-onset AT. The INSPIRE trial study was 
approved by the Medical Ethics Committee of the Erasmus 
MC Rotterdam, the Netherlands (MEC-2016-292), and 
registered at the Netherlands Trial Registry (NTR number: 
NL5843). The INSPIRE trial is a randomized controlled trial 
that investigated the effect of an online injury prevention 
program on the number or running-related injuries in run-
ners preparing for a running event.10 The online prevention 
program did not decrease the number of running-related in-
juries, which is why we can consider the included patients 
as a cohort.10
Extensive description of the methods is published by 
Fokkema et al11 Recruitment was from October 2016 until 
April 2017. Informed consent was obtained from all partic-
ipants, and their rights to privacy were protected. Runners 
received one baseline questionnaire ≤2  months before and 
three follow-up questionnaires 2 weeks before, 1 day after, 
and 1 month after a Dutch running event (5-42.2 km). The 
baseline questionnaire inquired information about age, sex, 
body mass index (BMI), running experience in years, run-
ning distance in the week before baseline questionnaire, 
runs per week, average hours ran per week in the previous 
3 months, average kilometers ran per week in the previous 
3 months, and average pace in minute per kilometer in the 
previous 3  months. The follow-up questionnaires inquired 
whether the runner had developed a running-related injury 
and on which location.
2.2 | Prospective follow-up study
For the current study, runners who developed a self-reported 
new-onset AT between event registration and 1 month after 
the running event were included. AT was defined as an in-
jury localized in the Achilles tendon caused by running, and 
one or more of the following criteria had to be met: (1) The 
injury caused a reduction in running distance, frequency, 
speed, or duration for at least 1 week; (2) the injury led to 
an appointment with a doctor and/or physiotherapist; and (3) 
medication was used to reduce symptoms.10 There was no 
question to distinguish between insertional AT and midpor-
tion AT, as there is yet no validated questionnaire-based ap-
proach to make this distinction. An follow-up questionnaire 
was sent 1 year after the running event to runners who re-
ported new-onset AT. This questionnaire was divided into six 
sections: (1) current symptoms of AT, (2) symptom sever-
ity, (3) healthcare consumption, (4) course of AT symptoms, 
(5) running activity, and (6) presence of metabolic disorders 
(Figure 1).
2.3 | Outcome measures
The primary outcome measure was the percentage of run-
ners who reported developing persisting symptoms localized 
in the Achilles tendon 1 year after development of new-onset 
AT. Persisting symptoms were expressed in a single question 
"Do you still experience symptoms of your Achilles tendi-
nopathy?" (Figure 1).
   | 3LAGAS et AL.
F I G U R E  1  Six different sections of the follow-up questionnaire with subdivided variables
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Secondary outcome measures were the symptom sever-
ity in runners 1  year after development of new-onset AT, 
expressed in the Victorian Institute of Sports Assessment-
Achilles tendinopathy (VISA-A) score, course of AT 
symptoms, healthcare consumption, running activity, and 
potential prognostic factors for developing persisting symp-
toms. Potential prognostic factors were sex, age, body mass 
index (BMI), running experience in years, running distance 
per week and previous AT (all reported in the baseline ques-
tionnaire before onset of AT), and adjustments in running ac-
tivity and having a metabolic disorder (both reported in the 
1-year follow-up questionnaire, based on the answers on the 
questions in Figure 1).
2.4 | Statistical analysis
To assess possible differences in baseline characteristics of 
runners with new-onset AT who completed and who did 
not complete the 1-year follow-up questionnaire, we used 
an independent-sample t test (normal distribution), Mann-
Whitney U test (no normal distribution), or chi-square test 
(categorical variables). A similar analysis was performed to 
assess possible differences in baseline characteristics and 
running activity between runners who reported persisting 
symptoms and runners who reported recovery. The percent-
age of runners reporting persisting symptoms was calculated 
by dividing the number of symptomatic runners by the num-
ber of recovered runners. Symptom severity was analyzed 
using descriptive statistics and expressed as mean VISA-A 
(standard deviation (SD)). Descriptive statistics were used 
to report the course of AT symptoms, healthcare consump-
tion, and running activity (as recorded with the questions 
in Figure  1). Potential prognostic factors for developing 
persisting symptoms were analyzed using a multivariable 
binary logistic regression model (ENTER method). Results 
were presented as odds ratio (OR) with 95% confidence in-
terval (CI).
In all statistical analysis, a P-value < .05 was deemed sig-
nificant. SPSS software (V.24.0.0.1; SPSS, Chicago, Illinois, 
USA) was used for statistical analysis.
3 |  RESULTS
A total of 1929 runners were included in the INSPIRE trial 
and completed at least one of the follow-up questionnaires, 
and 100 reported new-onset AT (5%). Of these runners with 
new-onset AT, 62 runners (62%) filled in the 1-year follow-
up questionnaire. One runner (1%) did not fully complete 
the VISA-A questionnaire. Runners who filled in the 1-year 
follow-up questionnaire were on average 5.2 years older than 
runners who did not fill in the 1-year follow-up questionnaire. 
Additionally, runners who completed the 1-year follow-up 
questionnaire registered more often for a full marathon and 
less for half a marathon (Supplementary File S1). Other base-
line characteristics were comparable.
3.1 | Persisting symptoms
In 32% of cases, runners reported having persisting symp-
toms. Table 1 describes differences in baseline character-
istics between runners with persisting AT symptoms and 
runners that did not have persisting symptoms (recovery 
group).
3.2 | Symptom severity
After 1 year, runners who completed the VISA-A score (61%) 
had a symptom severity of 85.1 (17.9), expressed in mean 
VISA-A score (SD). When dichotomizing the VISA-A score 
with a cutoff of ≥97 points on the VISA-A scale (normal 
range for healthy runners),12 64% of the runners scored <97 
points, while 36% of the runners scored ≥97 points. None of 
the runners who reported persisting symptoms had a VISA-A 
score of ≥97. Of runners who reported recovery, 52% had a 
VISA-A score of >97.
3.3 | Course of symptoms
The pain as a consequence of AT was most frequently de-
scribed as "gradually decreasing pain" (60%) (Table 2). This 
description was used by 70% of runners who reported re-
covery. There was a large variation within the group of run-
ners with persisting symptoms: 30% described their course 
as "gradually decreasing pain," followed by "persisting pain 
with slight fluctuations" (25%), "pain attacks without pain in 
between" (15%), "pain attacks with pain in between" (15%), 
"gradually increasing pain" (10%), and "persisting pain with 
pain attacks" (5%).
3.4 | Healthcare consumption
Over the course of 1-year follow-up, more than half of all 
runners (56%) visited a medical professional for their AT 
(Table 2). Runners who visited a medical professional and 
reported persisting symptoms had a median (interquartile 
range, IQR) of 5.0 (9.0) visits, and runners who reported 
recovery had a median (IQR) of 4.5 (4.0) visits. Most run-
ners visited a physiotherapist (48%, Table 2). Ultrasound was 
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the most frequently reported imaging tool (16%). Almost all 
runners used some form of treatment, of which relative rest 
(82%) and exercises (77%) were most popular. Descriptive 
statistics of applied treatments between runners with persist-
ing symptoms and runners who reported recovery are dis-
played in Supplementary File S2.
3.5 | Running activities
After development of new-onset AT, 66% of runners adjusted 
their running activities during the course of 1 year because of 
AT symptoms: 53% in frequency, 47% in speed, and 45% in 
duration (Table 2). One year after development of new-onset 
AT, 23% of runners still had adjusted their running activities 
because of AT symptoms.
Runners with persisting symptoms decreased the dis-
tance ran per week from median (IQR) 20.0km (20.0) at 
3  months before baseline to 15.0km (20.0) 3  months be-
fore 1-year follow-up (P = .041). There was no significant 
change in median (IQR) running hours per week from 
3.0 hours (2.0) to 2.0 hours (2.5) (P = .100), and there was 
no significant change in median (IQR) pace (5.0 min/km 
(1.0) vs 5.5 min/km (1.5), P = .329). Runners who reported 
recovery decreased their median (IQR) pace significantly 
from 5.0 min/km (1.0) to 6.0 min/km (1.3), P = .030, while 
hours per week (2.8 hours (2.6) vs 3.0 hours (2.0), P = .196) 
and kilometers per week (20.0 km (23.5) vs 20.0 km (26.3), 
P = .912) did not change significantly. There were no be-
tween-group differences in median running hours, kilome-
ters covered, or running pace.
3.6 | Prognostic factors for developing 
persisting symptoms
A higher running distance per week before onset of AT was 
associated with a lower risk of developing persisting symp-
toms (OR 0.9, 95% CI [0.9;1.0]). There was a tendency 
that having one of the metabolic disorders (OR 5.7, 95% CI 
[0.9;36.2]) was associated with an increased risk of devel-
oping persisting symptoms. There were no significant asso-
ciations between developing persisting symptoms and other 
included factors (Table 3).
4 |  DISCUSSION
This is the first study to report how many runners develop 
persisting symptoms at 1  year after new-onset AT. One 
Persisting symptoms Recovered
P-valueN
%/ mean (SD)/ 
median; IQR N




Sex (female) 35% 29% .608
Age (years) 49.0 (8.1) 46.2 (10.7) .318
Length (cm) 179.5 (9.7) 179.5 (10.3) .993
Weight (kg) 77.1 (12.3) 74.5 (12.0) .440




4.8; 9.5 4.3; 7.0 .928
Running distance 
per week (km)
13.5; 15.0 25.0; 25.0 .033*
Runs per week 2.0; 2.0 3.0; 1.0 .052
Event distance
5 km - 7% -
7.5 km - - -
10 km 30% 24% .629
21.1 km 25% 17% .753
42.2 km 45% 52% .831
Abbreviations: BMI, body mass index; IQR, interquartile range; SD, standard deviation.
*Statistically significant difference (p-value < 0.05) 
T A B L E  1  Baseline characteristics 
of the runners who reported persisting 
symptoms or recovery 1 year after new-
onset AT
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third of runners reported persisting symptoms 1  year after 
new-onset AT. One quarter still adjusted their running ac-
tivities one year after developing new-onset AT because of 
persisting AT symptoms. In runners that developed AT, a 
higher running distance per week before onset of AT was 
associated with a lower risk of developing persisting symp-
toms. Furthermore, we found a positive trend toward an 
association between having a metabolic disorder and devel-
oping persisting symptoms.
4.1 | Persisting symptoms
Johannsen et al13 reported that 37% of patients with chronic 
AT experience some degree of pain and reduced function 
after 10 years follow-up, which is a similar to the 32% of 
self-reported persisting symptoms in our study. Noticeable 
is the small difference in persisting symptoms between our 
1-year follow-up study and this 10-year follow-up study.13 
Other studies reported approximately 35%-60% of pa-
tients with chronic AT having persisting symptoms after 
a follow-up of 5  years or longer.4,14,15 The difference can 
be explained by the heterogeneity of the studies, as there 
were differences in the definition of recovery (self-reported 
recovery13-15 vs pain free4), type of AT (insertional, midpor-
tion,4,15 or a mix13,14), duration of AT (chronic AT vs4,14 a 
mix of new-onset AT and chronic AT13,15), and researched 
population (active patients4,14 vs a mix of active and seden-
tary patients13,15). Nevertheless, all studies, including ours, 
reported a relatively large subgroup of patients with persist-
ing symptoms. There is a need to better identify the charac-
teristics of this specific subgroup with persisting symptoms 
at an early stage.
The percentage of self-reported persisting symptoms 
(32%) was lower than the percentage with persisting symp-
toms according to the dichotomized VISA-A score (64%). 
This difference might be explained by the acceptance of 
limitations by the patient: The patient experiences no AT 
symptoms due to, for example, decreased sports activity. 
Therefore, patients might not report persisting symptoms due 
to acceptance of limitations, while the patient has not fully 
recovered to the pre-injury sports activity. For adequate ex-
pectation management, it is important to inform runners with 
new-onset AT that their symptoms might cause long-lasting 
adjustments in sports activity.
4.2 | Symptom severity
Symptom severity can be expressed with the validated 
VISA-A score (0-100 points, with 100 points representing 
full recovery). Patients reported a mean and SD of 85.1 (17.9) 
at 1 year after sustaining new-onset AT. We are the first to 
report symptom severity 1 year after development of new-
onset AT. The patient acceptable symptom state (PASS), a 
T A B L E  2  Course of AT symptoms, healthcare consumption, 






Course of AT symptoms
Gradually decreasing pain 37 60%
Gradually increasing pain 3 5%
Persisting pain with slight fluctuations 9 15%
Persisting pain with pain attacks 1 2%
Pain attacks without pain in between 5 8%
Pain attacks with pain in between 7 11%
Healthcare consumption
Visit of medical professional (yes) 35 56%
Physiotherapist 30 48%
General practitioner 7 11%
Medical specialist 4 6%
Othera 5 8%
Number of visits 5.0 (5.0)




Treatment applied (yes) 60 97%












Adjustments at 1-year follow-up 14 23%




Abbreviations: AT, Achilles tendinopathy; MRI, magnetic resonance imaging; 
SD, standard deviation.
aosteopath, podiatrist. 
   | 7LAGAS et AL.
value that represents the level of acceptable symptoms for 
the patient, is not yet determined for the VISA-A score.16 It 
is currently unknown how to interpret the symptom sever-
ity in relation to the patients’ experience of the symptoms. 
Determining the PASS for the VISA-A score will help fu-
ture studies to interpret whether the symptom severity will 
be deemed acceptable by the patient. The high variability of 
this outcome in this homogenous population also suggests 
that a subgroup of patients with persisting severe symptoms 
is present.
4.3 | Course of symptoms
The course of AT symptoms was by both runners with persist-
ing symptoms and runners who reported recovery most fre-
quently described as "gradually decreasing pain." However, 
the course of AT symptoms in runners with persisting symp-
toms was more heterogeneous, and runners chose more fre-
quently descriptions that included the word "fluctuations" or 
"pain attacks."
In a clinical setting, runners can be informed that the 
course of symptoms after onset of AT is gradually decreas-
ing in most cases. However, in case of recurring fluctua-
tions or pain attacks, it could be helpful to seek medical 
advice.
4.4 | Healthcare consumption
The majority of patients consulted a healthcare professional 
with a mean of almost 4 visits per patient. Almost all pa-
tients decided to apply some form of treatment. The use of 
treatment could influence the risk of developing persisting 
symptoms 1 year after new-onset AT. We think it is impor-
tant to point out that we chose not include this variable in the 
multivariable analysis, as almost all runners used any form of 
treatment. This would severely influence the outcome of the 
analysis. Furthermore, a randomized study design is neces-
sary for analyzing treatment effect on developing persisting 
symptoms.
4.5 | Running activities
One in four runners adjusted their running activities at 1 year 
after development of new-onset AT because of AT symptoms. 
Runners with persisting symptoms decreased the distance 
ran per week by 5 km, while runners who reported recovery 
slowed down their pace by 1 min/km. The slower pace in run-
ners who reported recovery fits the previously mentioned hy-
pothesis why the percentage of self-reported recovery is higher 
than recovery according to the dichotomized VISA-A score. 





%/ mean (SD)/ 
median; IQR N
%/ mean (SD)/ 
median; IQR OR (95% CI)
20 42
Sex (female) 35% 29% 2.8 (0.7;11.5)
Age (years) 49.0 (8.1) 46.2 (10.7) 1.0 (0.9;1.1)
BMI (kg/m2) 23.8 (2.3) 23.0 (2.4) 1.2 (0.9;1.7)
Running experience 
(years)
4.8; 9.5 4.3; 7.0 1.0 (1.0;1.1)
Running distance 
per week (km)
13.5; 15.0 25.0; 25.0 0.9 (0.9;1.0)*
Previous AT (yes) 40% 24% 2.6 (0.6;11.2)
Adjusted running 
activity (yes)a 
70% 64% 0.8 (0.2;3.1)
Any metabolic 
disorder (yes)b 
30% 12% 5.7 (0.9;36.2)
Abbreviations: AT, Achilles tendinopathy; BMI, body mass index; CI, confidence interval; IQR, interquartile 
range; OR, odds ratio; SD, standard deviation.
aadjusted running activity after development of new-onset AT. 
bincluded metabolic disorders are hypertension, hypercholesterolemia, and diabetes. 
*Statistical significant difference (p-value < 0.05). 
T A B L E  3  Potential prognostic factors 
for developing persisting symptoms, 
analyzed with a multivariable binary logistic 
regression analysis
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have not returned to their pre-injury level of sports. Although 
AT occurs frequently in active persons, there are no other stud-
ies describing adjustments in (running) activity because of AT 
symptoms.
4.6 | Prognostic factors for developing 
persisting symptoms
We analyzed a number of potential prognostic factors for 
the development of persisting symptoms 1 year after new-
onset AT. Surprisingly, a higher running distance per week, 
reported before onset of AT, was associated with a lower 
risk of developing persisting symptoms. Although this re-
sult is difficult to explain, we propose two plausible hy-
potheses. First, runners with high training loads might have 
had more constant training loads than the runners with low 
training load. This high variability in training load leads to 
"spikes" in training load, and theoretically, this can be a 
prognostic factor for persisting symptoms.17 We did, how-
ever, not record changes in training load. A second hypoth-
esis is that we only found an association due to the relatively 
low number of runners with AT. It is interesting to study 
whether there is a subgroup with a different training behav-
ior over time that is more susceptible to develop persisting 
symptoms.
There was a tendency toward an association between hav-
ing a metabolic disorder and developing persisting symptoms. 
We selected metabolic disorders (hypertension, hypercho-
lesterolemia, and diabetes) that were associated with AT in 
previous literature.7,9,18 We noticed a similar tendency for 
BMI, which is part of the metabolic syndrome, although the 
clinical relevance of BMI was less striking (mean difference 
of 0.8 kg/m2). Metabolic disorders influence the tendon via 
different mechanisms, which can lead to matrix destruction 
due to systemic inflammation and hypoxia.19,20 As inflam-
mation is part of many metabolic disorders,7 it could main-
tain the chronic state of the tendinopathy and prevents proper 
healing. Tendinopathy could prevent patients from exercising 
and worsen the metabolic state.21 This could eventually form 
a vicious circle: Patient starts exercising to improve their 
metabolic state, the metabolic disorder leads to AT, which 
hampers mobility and the metabolic state is not improved or 
even worsens.7
4.7 | Strengths and limitations
A major strength of our study is the number of included 
cases, which increases the likelihood to identify prog-
nostic factors for the course of AT. As we report more 
than 50 cases, we were able to detect moderate-to-strong 
associations.22 A limitation of this study is using online 
questionnaires to inquire about injuries. A strict injury 
definition, reported in the original publication by Fokkema 
et al,10 was used to prevent contamination of the data by 
injuries that were not actually injuries. As distinguishing 
between insertional AT and midportion AT through an on-
line questionnaire has not been validated, we chose not to 
collect and present this information. We therefore do not 
know the difference in prognosis between these two enti-
ties. Another limitation was the response rate of 62%. The 
responding group consisted of slightly older runners and 
registered more often for a full marathon, which makes 
the results of this study more appropriate for slightly older 
marathon runners. Another possible limitation is recall 
bias, especially for the presence of metabolic disorder. 
As metabolic disorders develop over a longer period of 
time, we assume that they were already present at base-
line. However, we did not perform physical examination 
or blood tests. It could be that runners have had an un-
derlying metabolic disorder, but were not diagnosed. This 
potential bias is possibly existent in both the recovered 
and non-recovered groups.
4.8 | Recommendation for future research
Our study shows an interesting association between running 
distance per week and persisting symptoms. It is currently 
unclear how the runners exactly adjusted their running activi-
ties. Global Positioning System (GPS) data are often used by 
runners to evaluate personal progress, and it offers a valid 
alternative to subjective reporting.23 It would be interest-
ing to analyze the association between running distance per 
week, analyzed with GPS data, and development of persist-
ing symptoms in runners 1 year after new-onset AT, in order 
to identify optimal training load adjustments for this patient 
group.
A tendency toward an interesting association between 
metabolic disorders and persisting symptoms was also iden-
tified. As runners could have undiagnosed metabolic disor-
ders, we propose to perform a large prospective follow-up 
study with the use of objective outcome measures represent-
ing metabolic disorder.
5 |  CONCLUSION
One third of runners develop persisting symptoms 1  year 
after new-onset AT. One year after developing new-onset 
AT, one quarter of runners still had adjusted their running ac-
tivities because of AT symptoms. A higher running distance 
per week, reported before new-onset AT, was associated with 
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a lower risk of developing persisting symptoms. There was a 
positive trend toward an association between metabolic dis-
orders and developing persisting symptoms. Future research 
is needed for in-depth analysis of the association between ex-
ternal and internal prognostic factors and the development of 
persisting symptoms.
5.1 | Perspective
One third of runners develop persisting symptoms 1 year 
after new-onset Achilles tendinopathy and one quarter of 
runners still had to adjust their running activities due to 
symptoms. We identified that a higher running distance 
per week before developing new-onset AT is associated 
with a lower risk of developing persisting symptoms. By 
describing the course of symptoms and the effect on run-
ning activities, this study supports the clinician in provid-
ing evidence-based information to the patient and forming 
adequate expectations.
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